Barclays PLC Arcellx, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Barclays PLC holds 85,322 shares of ACLX stock, worth $6.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,322

Previous 85,322 -0.0%

Holding current value

$6.62 Million

Previous $7.13 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$50.91 - $86.61 $2.44 Million - $4.14 Million	47,852 Added 127.71%	85,322 $7.13 Million
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $111,069 - $149,566	-2,233 Reduced 5.62%	37,470 $2.07 Million
Q1 2024 May 15, 2024	SELL	$51.85 - $73.49 $4.65 Million - $6.59 Million	-89,723 Reduced 69.32%	39,703 $2.76 Million
Q4 2023 Feb 15, 2024	BUY	$31.75 - $57.99 $1.37 Million - $2.51 Million	43,239 Added 50.17%	129,426 $7.18 Million
Q3 2023 Nov 07, 2023	BUY	$31.51 - $37.4 $333,722 - $396,103	10,591 Added 14.01%	86,187 $3.09 Million
Q2 2023 Aug 03, 2023	BUY	$27.49 - $46.9 $453,090 - $773,005	16,482 Added 27.88%	75,596 $2.39 Million
Q1 2023 May 04, 2023	SELL	$26.92 - $33.94 $274,799 - $346,459	-10,208 Reduced 14.73%	59,114 $1.82 Million
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $176,696 - $339,405	10,285 Added 17.42%	69,322 $2.15 Million
Q3 2022 Nov 03, 2022	BUY	$16.67 - $22.04 $975,928 - $1.29 Million	58,544 Added 11875.05%	59,037 $1.11 Million
Q2 2022 Aug 12, 2022	SELL	$7.21 - $24.43 $7,109 - $24,087	-986 Reduced 66.67%	493 $9,000
Q1 2022 May 16, 2022	BUY	$12.97 - $19.14 $19,182 - $28,308	1,479 New	1,479 $20,000

Others Institutions Holding ACLX

# of Institutions

204

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.4B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account